Credit Suisse: Keep An Eye On These 6 Healthcare Stocks In 2015

In a recent report, analysts at Credit Suisse outlined their 2015 outlook for Healthcare stocks. Here’s a breakdown of their top stocks to own in 2015.
1. Bristol-Myers Squibb Co BMY: Analysts believe that the company’s positioning in the immune-oncology space and the company’s intrinsic value are more than enough to justify its premium price to earnings ratio. Price target: $66.00
2. Celgene Corp CELG: Analysts like Celgene’s strong core business growth centered around its three key drugs (Pomalyst, Abraxane, Otezla) and its exciting pipeline (GED-301, MOR-202) and predict continued growth in upcoming years. Price target: $145.00
3. PTC Therapeutics Inc PTCT: Analysts believe the European approval of Translarna for treatment of muscular dystrophy has eliminated much of the risk in owning the stock. They see European approval for treatment of cystic fibrosis, more rapid U.S. regulatory strategy for muscular dystrophy treatment and updates on the spinal muscular atrophy treatment pipeline as potential catalysts for the stock. Price target: $66.00
4. Aetna Inc AET: Analysts see long-term growth potential in the company and praise the diversification of its portfolio. They believe that its 2015 guidance is conservative and that it will soon no longer trade at a large discount to its peers. Price target: $103
5. Cardinal Health Inc CAH: Analysts point to the company’s strong cash flow and under-levered balance sheet as evidence of the potential for M&A activity or the institution of a share repurchase program. Price target: $88.00
6. HeartWare International Inc HTWR: Analysts like the stock’s valuation and believe that the company’s next-generation left ventricular assist devices trial will soon be approved to commence by the FDA. Price target: $90.00